The direct electrophysiologic effects of disopyramide phosphate in the transplanted human heart.
- 1 January 1983
- journal article
- research article
- Published by Wolters Kluwer Health in Circulation
- Vol. 67 (1) , 38-45
- https://doi.org/10.1161/01.cir.67.1.38
Abstract
To evaluate the direct electrophysiologic effects of i.v. disopyramide phosphate and to differentiate these effects from its autonomically mediated actions, we administered the drug (2 mg/kg over 5 minutes) during electrophysiologic study to eight cardiac transplant recipients who had documented functional cardiac denervation. After disopyramide, the cycle length of the denervated donor right atrium increased from 626 +/- 129 to 716 +/- 148 msec (mean +/- SD, p less than 0.001), whereas that of the innervated recipient atrium decreased from 846 +/- 195 to 659 +/- 99 msec (p less than 0.02). There were small increases in both the sinus node recovery time (1128 +/- 616 to 1198 +/- 592 msec, p less than 0.05) and corrected sinus node recovery time (440 +/- 418 to 489 +/- 409 msec, p less than 0.02) of the donor atrium, whereas the recovery times of the recipient atrium shortened (sinus node recovery time, 1298 +/- 218 to 1218 +/- 196 msec; corrected sinus node recovery time, 464 +/- 108 to 410 +/- 115 msec). Disopyramide markedly prolonged all conduction intervals. The PA interval increased from 47 +/- 16 to 54 +/- 17 msec (p less than 0.01), the AH interval from 55 +/- 12 to 78 +/- 12 msec (p less than 0.001), the HV interval from 38 +/- 9 to 58 +/- 13 msec (p less than 0.001), the QRS duration from 93 +/- 18 to 129 +/- 34 msec (p less than 0.001) and the QT interval from 339 +/- 23 to 403 +/- 39 msec (p less than 0.001). There was no significant change in the effective refractory period of the atrium, ventricular or atrioventricular node. The functional refractory period of the atrioventricular node increased from 369 +/- 34 to 395 +/- 31 msec (p less than 0.001). The electrophysiologic effects of disopyramide in the denervated heart are markedly depressant. In the innervated normal heart, the majority of these effects are counteracted by the drug's autonomically mediated anticholinergic actions.This publication has 35 references indexed in Scilit:
- Efficacy of Intravenous Disopyramide in the Termination of Supraventricular ArrhythmiasThe Journal of Clinical Pharmacology, 1978
- Disopyramide: Serum level and arrhythmia conversionAmerican Heart Journal, 1976
- Electrophysiologic effects of the antiarrhythmic agent disopyramide phosphateThe American Journal of Cardiology, 1975
- Effects of disopyramide phosphate (norpace) on electrophysiologic properties of isolated canine cardiac purkinje fibersThe American Journal of Cardiology, 1975
- Arrhythmias after cardiac transplantationThe American Journal of Cardiology, 1974
- Electrophysiologic effects of atropine on atrioventricular conduction studied by his bundle electrogramThe American Journal of Cardiology, 1974
- Electrophysiological evaluation of disopyramide in manAmerican Heart Journal, 1973
- Cardiovascular effects of a newer antiarrhythmic agent, disopyramide phosphateAmerican Heart Journal, 1972
- Observations on the behavior of recipient atria after cardiac transplantation in manThe American Journal of Cardiology, 1972
- Evaluation of cardiac conduction in the cardiac catheterization laboratoryThe American Journal of Cardiology, 1972